Poster SESSIONS
64
Poster, 24 June 2014
P-25-028
Associations of obsessive-compulsive
symptoms with clinical features and neuro-
cognitive functioning in patients with schizo-
phrenia according to the stage of illness
Sung-Wan Kim, Gwangju, Republic of Korea
B.-O. Jeong, J.-M. Kim, I.-S. Shin, Y.-H. Lee, M.
Hwang, M. Berk, P. McGorry, J.-S. Yoon
P-25-029
Comparison of attitudes toward long-acting
injectable antipsychotics among psychia-
trists and patients
Sung-Wan Kim, Gwangju, Republic of Korea
Y.-H. Lee, J.-E. Jang, T. Yoo, J.-M. Kim, I.-S.
Shin, J.-S. Yoon
P-25-030
Effects of antipsychotic drugs on the expres-
sion of synapse-associated proteins in the
frontal cortex of rats subjected to immobi-
lization stress
Young Hoon Kim, Busan, Republic of Korea
S. W. Park, Y. S. You, C. H. Lee, M. K. Seo, H.
Y. Jo, J. G. Lee, B. J. Lee, J. H. Baek, S. J. Lee
P-25-031
Effect of add on aripiprazole on antipsy-
chotic induced hyperprolactinemia
Vijaya Kumar Kg, Bengaluru, India
G. Venkatasubramanian, S. Varambally
P-25-032
Treatment patterns of long-acting injectable
antipsychotics in the province of quebec
Jean Lachaine, Montreal, Canada
M.-E. Lapierre, N. Abdalla, A. Rouleau, E. Stip
P-25-033
Healthcare costs before and after initiation
of long-acting injectable antipsychotics in
the province of Quebec
Jean Lachaine, Montreal, Canada
M.-E. Lapierre, N. Abdalla, A. Rouleau, E. Stip
P-25-034
Improvement on dyslipidemia and negative
symptoms by ziprasidone augmentation in
clozapine-resistant patients with schizo-
phrenia
Hwang-Bin Lee, Seoul, Republic of Korea
S.-J. Yim, M. Sim, H.-K. Kang
P-25-035
Metabolic syndrome and its impact on health
related quality of life and body image in Ko-
rean patients with schizophrenia
Sang Yeol Lee, Iksan, Republic of Korea
S. K. Chung
P-25-036
Effects of environmental context and drug
dose on MK-801 sensitisation in rats
Emilia Lefevre, Brisbane, Australia
D. Eyles, T. Burne
P-25-037
Long-term effectiveness and safety of
blonanserin in patients with first-episode
schizophrenia: A one-year open-label study
Tomomi Tenjin, Kawasaki City, Kanagawa,
Japan
S. Miyamoto, Y. Ninomiya, N. Miyake, S. Ogino,
H. Harada, Y. Yamashita, Y. Kaneda, T. Sumi-
yoshi, N. Yamaguchi
P-26
POSTER SESSION
17:15–18:45
Hall B
Post-traumatic stress disorders
P-26-001
Atypical antipsychotics in the treatment of
posttraumatic stress disorder
Won-Myong Bahk, Seoul, Republic of Korea
H. R. Wang, Y. S. Woo, K. H. Lee, B.-H. Yoon
P-26-002
Association between D2 Dopamine Recep-
tor (DRD2) gene and posttraumatic stress
disorder
Haegyung Chung, Seoul, Republic of Korea
T. Kim, J. Choi, H. So, S. Kang
P-26-003
PTSD, outcome and its up to date treatments
Habib Rabbani, Paris, France
P-26-004
The effect of early post-stressor intervention
with agomelatine on behavioral and molec-
ular responses in an animal model of post-
traumatic stress disorder
Joseph Zohar, Tel Aviv, Israel
H. Cohen
